[go: up one dir, main page]

BR112016008039A2 - polipeptídeos do fator vii da coagulação - Google Patents

polipeptídeos do fator vii da coagulação

Info

Publication number
BR112016008039A2
BR112016008039A2 BR112016008039A BR112016008039A BR112016008039A2 BR 112016008039 A2 BR112016008039 A2 BR 112016008039A2 BR 112016008039 A BR112016008039 A BR 112016008039A BR 112016008039 A BR112016008039 A BR 112016008039A BR 112016008039 A2 BR112016008039 A2 BR 112016008039A2
Authority
BR
Brazil
Prior art keywords
factor vii
coagulation factor
vii polypeptides
polypeptides
relates
Prior art date
Application number
BR112016008039A
Other languages
English (en)
Inventor
Østergaard Henrik
Hvilsted Olsen Ole
S Gandhi Prafull
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BR112016008039A2 publication Critical patent/BR112016008039A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a polipeptídeos do fator vii de coagu-lação modificado que exibem um aumento da resistência à inativação à antitrombina e atividade proteolítica aumentada. a presente invenção também se refere a construções polinucleotídicas que codificam tais polipeptídeos, vetores e células hospedeiras que compreendem e ex-pressam tais polinucleotídeos, composições farmacêuticas, utilizações e métodos de tratamento.
BR112016008039A 2013-10-15 2014-10-15 polipeptídeos do fator vii da coagulação BR112016008039A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13188715 2013-10-15
US201361895438P 2013-10-25 2013-10-25
EP14154875 2014-02-12
PCT/EP2014/072076 WO2015055692A1 (en) 2013-10-15 2014-10-15 Coagulation factor vii polypeptides

Publications (1)

Publication Number Publication Date
BR112016008039A2 true BR112016008039A2 (pt) 2017-10-17

Family

ID=52810172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008039A BR112016008039A2 (pt) 2013-10-15 2014-10-15 polipeptídeos do fator vii da coagulação

Country Status (11)

Country Link
US (4) US9371370B2 (pt)
EP (1) EP3058066A1 (pt)
JP (1) JP2016537321A (pt)
KR (1) KR20160065925A (pt)
CN (1) CN105637088A (pt)
AU (1) AU2014336252A1 (pt)
BR (1) BR112016008039A2 (pt)
CA (1) CA2927756A1 (pt)
IL (1) IL244594A0 (pt)
MX (1) MX2016004702A (pt)
WO (1) WO2015055692A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060397A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Factor vii conjugates
CN105637088A (zh) 2013-10-15 2016-06-01 诺和诺德保健股份有限公司 凝固因子vii多肽
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
JP6981973B2 (ja) * 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
KR20210094293A (ko) 2020-01-21 2021-07-29 김수호 차량용 핸들 장치 및 이를 포함하는 차량운전 보조 시스템

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
EP2226385B1 (en) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
MXPA04003333A (es) 2001-10-10 2006-02-22 Neose Technologies Inc Remodelado y glicoconjugacion de peptidos.
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP2007522805A (ja) 2004-02-03 2007-08-16 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 新規化合物
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
ES2434032T3 (es) 2005-06-17 2013-12-13 Novo Nordisk Health Care Ag Compuestos de FVIIA diméricos y multiméricos
CA2619969A1 (en) 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
US20090055942A1 (en) * 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
EP2532369B1 (en) 2006-12-15 2017-11-01 Baxalta GmbH Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
US20100166729A9 (en) 2007-04-13 2010-07-01 Madison Edwin L Modified factor VII polypeptides and uses thereof
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2773755C (en) 2008-09-09 2017-04-25 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CN102482340B (zh) 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
WO2011092242A1 (en) 2010-01-28 2011-08-04 Novo Nordisk Health Care Ag Factor vii fusion polypeptides
JP5826772B2 (ja) 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
WO2014060397A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Factor vii conjugates
WO2014060401A1 (en) * 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP2970933A2 (en) 2013-03-12 2016-01-20 Novo Nordisk A/S Thrombin sensitive coagulation factor x molecules
CN105637088A (zh) 2013-10-15 2016-06-01 诺和诺德保健股份有限公司 凝固因子vii多肽
AR099328A1 (es) 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii

Also Published As

Publication number Publication date
CN105637088A (zh) 2016-06-01
US20180142227A1 (en) 2018-05-24
US20160120992A1 (en) 2016-05-05
MX2016004702A (es) 2016-07-22
JP2016537321A (ja) 2016-12-01
AU2014336252A1 (en) 2016-04-07
CA2927756A1 (en) 2015-04-23
US20150105321A1 (en) 2015-04-16
KR20160065925A (ko) 2016-06-09
EP3058066A1 (en) 2016-08-24
US9370583B2 (en) 2016-06-21
IL244594A0 (en) 2016-04-21
US9371370B2 (en) 2016-06-21
US20170096655A1 (en) 2017-04-06
WO2015055692A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
BR112016008039A2 (pt) polipeptídeos do fator vii da coagulação
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
MX384628B (es) Polipéptidos que tienen actividad de transgalactosilación.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CR20150578A (es) Heterociclos bicíclicos como inhibidores de fgfr
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
MX376824B (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
UY34643A (es) Derivados de 5-alquinilo piridina como inhibidores de apoptosis,composiciones farmacéuticas y sus usos como miméticos smac
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112019004594A2 (pt) terapia genética para pacientes com anemia de fanconi
BR112018010802A2 (pt) polipeptídeos que inibem cd40l
MX2019007152A (es) Peptido novedoso.
BR112019011053A2 (pt) moduladores da atividade do complemento
MX2020006510A (es) Peptido novedoso.
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]